Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx Corporation (NASDAQ: LUNG) reported promising interim results from the CONVERT clinical trial presented at the 2022 European Respiratory Society (ERS) International Conference. The trial demonstrated that the AeriSeal System successfully closed collateral air channels in 78% of patients with severe COPD/emphysema, making them eligible for Zephyr Endobronchial Valves. Notable improvements were observed in lung function (FEV1 increase of 19.7%), quality of life (SGRQ score decrease of 15.1), and exercise capacity (Six-Minute Walk Distance increase of 77.2 meters).
Pulmonx Corporation (NASDAQ: LUNG) has announced promising interim results from the CONVERT Study presented at the 2022 European Respiratory Society Conference. The study indicates that the AeriSeal System successfully converted collateral ventilation status in 78% of patients, enabling them to receive Zephyr Valves treatment. The trial demonstrated a mean Target Lobe Volume Reduction of over 1 liter, improving lung function by 19.7%, quality of life, and exercise capacity. No serious adverse reactions were noted in recent studies, marking a significant advancement in the treatment of severe COPD.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, announced its participation in two upcoming investor conferences. The company will speak at the Wells Fargo Healthcare Conference in Boston on September 7, 2022, at 6:10 AM PT/9:10 AM ET, and the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 13, 2022, at 1:40 PM PT/4:40 PM ET. A live webcast of the presentations will be accessible on Pulmonx’s investor website.
Pulmonx reported strong Q2 2022 results with worldwide revenue reaching $14.0 million, a 14% increase year-over-year. U.S. revenue surged 31% to $8.6 million, driven by Zephyr Valve procedures. Gross margin improved to 75%, up from 74% in Q2 2021. However, operating expenses rose 14% to $24.8 million, contributing to a net loss of $14.6 million or $0.40 per share. Pulmonx maintains its full-year revenue guidance of $55-$60 million.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 10, 2022, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be accessible on the company's Investors page. Pulmonx is known for its Zephyr® Endobronchial Valve, which has treated over 25,000 patients worldwide, and received FDA premarket approval as a breakthrough device.
Pulmonx Corporation (NASDAQ: LUNG) will announce its Q2 2022 financial results on August 2, 2022, after market close. A conference call will be held at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. Pulmonx is a leader in minimally invasive treatments for lung disease, notably through its FDA-approved Zephyr® Endobronchial Valve, which is available in over 25 countries. The company has treated more than 25,000 patients with over 100,000 valves used.
Pulmonx Corporation (LUNG) reported Q1 2022 financial results, highlighting a 17% increase in worldwide revenue to $10.8 million compared to Q1 2021. U.S. revenue surged 40% to $6.0 million, driven by growth in Zephyr Valve procedures. Gross margin improved to 75%, up from 72%, despite operating expenses rising 24% to $23.8 million. The net loss for the quarter was $15.8 million, or $0.43 per share. Pulmonx maintains its 2022 revenue outlook of $55 million to $60 million amidst ongoing investments and challenges from COVID and foreign exchange rates.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 12:40 PM PT. A live and archived webcast will be available on the company's investor website. Pulmonx is known for its innovative Zephyr Valve, which treats patients with severe emphysema/COPD and has received FDA breakthrough device designation. The valve is commercialized in over 25 countries, with more than 100,000 units used to date.
Pulmonx Corporation (Nasdaq: LUNG) will release its Q1 2022 financial results on May 3, 2022, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can participate by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 2575271. The event will also be accessible via a live and archived webcast on the company's website.
Pulmonx Corporation (LUNG) reported strong financial results for Q4 and full year 2021, with Q4 revenue reaching $13.7 million (+39%) and full-year revenue at $48.4 million (+48%). The company achieved a gross margin of 74.8% in Q4, up from 72.0% in 2020. Operating expenses increased by 38% to $22.6 million in Q4, leading to a net loss of $13.0 million. For 2022, Pulmonx forecasts revenues between $55 million and $60 million, despite ongoing COVID-19 impacts.